These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34791894)

  • 1. Asciminib as a new option in the treatment of chronic myeloid leukemia.
    İbiş B; Tiribelli M; Eşkazan AE
    Future Oncol; 2021 Dec; 17(36):5003-5005. PubMed ID: 34791894
    [No Abstract]   [Full Text] [Related]  

  • 2. Asciminib in chronic myeloid leukemia: many questions still remain to be answered.
    Eşkazan AE
    Blood Cancer J; 2021 Apr; 11(4):81. PubMed ID: 33927187
    [No Abstract]   [Full Text] [Related]  

  • 3. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Hall KH; Brooks A; Waller EK
    Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
    [No Abstract]   [Full Text] [Related]  

  • 5. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
    Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
    N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance.
    Okamoto N; Yagi K; Imawaka S; Takaoka M; Aizawa F; Niimura T; Goda M; Miyata K; Kawada K; Izawa-Ishizawa Y; Sakaguchi S; Ishizawa K
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1214. PubMed ID: 39031848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
    Okabe S; Moriyama M; Gotoh A
    Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
    Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
    Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asciminib as a third line option in chronic myeloid leukemia.
    Laganà A; Scalzulli E; Carmosino I; Martelli M; Breccia M
    Int J Hematol; 2023 Jan; 117(1):16-23. PubMed ID: 35930119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Yeung DT; Shanmuganathan N; Hughes TP
    Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting.
    Yılmaz R; Eşkazan AE
    Future Oncol; 2023 Mar; 19(8):545-547. PubMed ID: 37039036
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
    Qiang W; Antelope O; Zabriskie MS; Pomicter AD; Vellore NA; Szankasi P; Rea D; Cayuela JM; Kelley TW; Deininger MW; O'Hare T
    Leukemia; 2017 Dec; 31(12):2844-2847. PubMed ID: 28819281
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
    Garcia-Gutiérrez V; Luna A; Alonso-Dominguez JM; Estrada N; Boque C; Xicoy B; Giraldo P; Angona A; Alvarez-Larrán A; Sanchez-Guijo F; Ramírez MJ; Mora E; Vélez P; Rosell A; Colorado Araujo M; Cuevas B; Sagüés M; Cortes M; Encinas MP; Casado Montero LF; Moreno Vega M; Serrano L; Gomez V; Garcia-Hernandez C; Lakhwani S; Paz Coll A; de Paz R; Suarez-Varela S; Fernandez-Ruiz A; Perez Lopez R; Ortiz-Fernández A; Jiménez-Velasco A; Steegmann-Olmedillas JL; Hernández-Boluda JC
    Blood Cancer J; 2021 Feb; 11(2):16. PubMed ID: 33563899
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
    Réa D; Hughes TP
    Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic approaches in chronic myeloid leukemia.
    Özgür Yurttaş N; Eşkazan AE
    Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
    Chee L; Lee N; Grigg A; Chen M; Schwarer A; Szer J; Ratnasingam S; Raj S; Lukito P; Yeung D; Hughes T; Shanmuganathan N
    Intern Med J; 2024 Jul; 54(7):1214-1218. PubMed ID: 38884158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asciminib: First Approval.
    Deeks ED
    Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.
    G Lindström HJ; Friedman R
    BMC Cancer; 2020 May; 20(1):397. PubMed ID: 32380976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
    Curik N; Laznicka A; Polivkova V; Krizkova J; Pokorna E; Semerak P; Suchankova P; Burda P; Hochhaus A; Machova Polakova K
    Leukemia; 2024 Jun; 38(6):1415-1418. PubMed ID: 38615117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.